Gilead’s Price Battle with Express Scripts
Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival
By Caroline Humer
(Reuters) – The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc’s newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc’s treatments after trying for nearly a year to win a deeper discount.
Express Scripts’ move reignited investor concerns that pharmaceutical companies will have to bow to pricing pressure from U.S. insurers and lawmakers over novel medications whose cost can reach hundreds of thousands of dollars for some diseases.
Continue reading this entire article:
https://news.yahoo.com/express-scripts-cover-abbvie-hepatitis-c-drug-drops-050323412–finance.html